A detailed history of Virtus ETF Advisers LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 30,078 shares of PHAT stock, worth $268,596. This represents 0.26% of its overall portfolio holdings.

Number of Shares
30,078
Previous 30,078 -0.0%
Holding current value
$268,596
Previous $309,000 75.73%
% of portfolio
0.26%
Previous 0.16%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$8.97 - $12.05 $182,781 - $245,542
20,377 Added 210.05%
30,078 $309,000
Q1 2024

May 15, 2024

SELL
$6.21 - $11.05 $4,135 - $7,359
-666 Reduced 6.42%
9,701 $103,000
Q4 2023

Feb 15, 2024

BUY
$6.99 - $10.71 $18,334 - $28,092
2,623 Added 33.87%
10,367 $94,000
Q3 2023

Nov 07, 2023

SELL
$10.26 - $15.7 $7,910 - $12,104
-771 Reduced 9.05%
7,744 $80,000
Q2 2023

Aug 14, 2023

BUY
$7.28 - $14.32 $61,989 - $121,934
8,515 New
8,515 $121,000
Q3 2022

Nov 14, 2022

BUY
$6.46 - $12.11 $781 - $1,465
121 Added 0.72%
16,847 $187,000
Q2 2022

Aug 12, 2022

BUY
$6.2 - $15.5 $50,536 - $126,340
8,151 Added 95.06%
16,726 $141,000
Q1 2022

May 16, 2022

SELL
$11.55 - $20.06 $5,832 - $10,130
-505 Reduced 5.56%
8,575 $117,000
Q4 2021

Feb 14, 2022

BUY
$17.83 - $33.15 $52,241 - $97,129
2,930 Added 47.64%
9,080 $179,000
Q3 2021

Nov 15, 2021

SELL
$30.69 - $36.83 $10,004 - $12,006
-326 Reduced 5.03%
6,150 $197,000
Q2 2021

Aug 10, 2021

SELL
$32.66 - $39.87 $9,046 - $11,043
-277 Reduced 4.1%
6,476 $219,000
Q1 2021

May 17, 2021

BUY
$33.86 - $48.68 $3,995 - $5,744
118 Added 1.78%
6,753 $254,000
Q4 2020

Feb 12, 2021

BUY
$33.22 - $50.26 $13,055 - $19,752
393 Added 6.3%
6,635 $220,000
Q3 2020

Nov 13, 2020

SELL
$29.24 - $40.19 $24,386 - $33,518
-834 Reduced 11.79%
6,242 $229,000
Q2 2020

Aug 05, 2020

BUY
$25.06 - $54.6 $177,324 - $386,349
7,076 New
7,076 $233,000

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $350M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.